Monday May 21, 2018
Home India Private hospi...

Private hospitals deny access: Dengue claims son, Parents commit suicide

0
//
102
source: www.cafleurebon.com
Republish
Reprint

dengueBy Newsgram Staff Writer

New Delhi: Lakshman Chandra Raut (35) and Babita Raut (30) committed suicide by jumping from the fourth floor of a building when their seven-year-old son Avinash Raut died of dengue, said Delhi Police on Saturday.

Police said the couple hailing from Odisha jumped from their rented accommodation in the Lado Sarai area of south Delhi on Wednesday around 12.15 am. The parents have left a suicide note in Odia explaining that they were responsible for their own actions.

A suicide note was also recovered from the possession of the couple in which it was mentioned that they were in extreme shock over the death of their son. The note was written in Odia. The couple also mentioned that nobody is responsible for their act and that they were responsible for their decision,” the officer said.

After being diagnosed with the symptoms of dengue, Avinash was denied admission in five private hospitals, police said. He was finally admitted on September 4 but died during treatment on September 8, unable to make up for the lost time.

The Delhi government has issued a show-cause notice to these hospitals.

Moolchand Khairati Ram Hospital, Aakash Hospital, Saket City Hospital, Max Hospital (Saket) and Irene Hospital (Kalkaji) have been asked to reply in a month as to why their registration should not be cancelled for refusing emergency medical care to the deceased child,” said a Delhi government official.

While Health Minister Satyendra Jain promised stringent steps to be taken in the case, the Union Health Minister J.P. Nadda went a step further: “I have ordered an inquiry into the incident reported in the media involving the death of a child in Delhi due to dengue and the suicide by his parents. Guilty won’t be spared.”

The Central government is  also probing into the matter.

(With inputs from IANS)

 

Click here for reuse options!
Copyright 2015 NewsGram

Next Story

Dengue Vaccine Should Not Be Used Widely: UN Health Agency

UN Health Agency issued an important statement regarding the dengue vaccine

0
//
21
Dengue vaccine.
A Manila Health officer shows off a pair of vials of the anti-dengue vaccine Dengvaxia after being recalled from local government health centers Tuesday, Dec. 5, 2017 in Manila, Philippines. The World Health Organization says the first-ever vaccine for dengue needs to be dealt with in "a much safer way," meaning that the shot should mostly be given to people who have previously been infected with the disease. VOA

The World Health Organization says the first-ever vaccine for dengue needs to be dealt with in “a much safer way,” meaning that the shot should mostly be given to people who have previously been infected with the disease.

In November, the vaccine’s manufacturer, Sanofi Pasteur, said people who had never been sickened by dengue before were at risk of developing a more serious disease after getting the shot.

After a two-day meeting this week, WHO’s independent vaccines group said it now had proof the vaccine should only be used “exclusively or almost exclusively in people who have already been infected with dengue.”

Also Read: Anti-dengue Antibody Drug May Neutralize Zika Virus

The U.N. health agency said a test should be developed so doctors would be able to quickly tell if people had previously been sickened by dengue – but the group acknowledged doing that so isn’t straightforward.

“We see significant obstacles in using the vaccine this way, but we are confident this also spurs the development of a rapid diagnostic test,” said Dr. Joachim Hombach, executive secretary of WHO’s expert group, during a news conference Thursday.

Representational image for dengue vaccination
Representational image. Wikimedia Commons

Sanofi said last year that doctors should consider whether people might have been previously infected with dengue before deciding whether they should risk getting immunized. The company said it expected to take a 100 million euro ($118 million) loss based on that news.

People who catch dengue more than once can be at risk of a hemorrhagic version of the disease. The mosquito-spread virus is found in tropical and sub-tropical climates across Latin and South America, Asia, Africa and elsewhere. It causes a flu-like disease that can cause joint pain, nausea, vomiting and a rash. In severe cases, dengue can result in breathing problems, hemorrhaging and organ failure.

About half the world’s population is at risk of dengue; WHO estimates that about 96 million people are sickened by the viral infection every year.

Also Read: Dengue fever may increase risk of stroke: Study

Following Sanofi’s announcement last year, the Philippines halted its dengue immunization program, the world’s first national vaccination program for dengue. The government also demanded a refund of more than 3 billion pesos ($59 million) from Sanofi and is considering further legal action.

In February, the Philippines said the vaccine was potentially linked to the deaths of three people: all of them died of dengue despite having received the vaccine.

The country imposed a symbolic fine of $2,000 on Sanofi and suspended the vaccine’s approval, charging that the drugmaker broke rules on how the shot was registered and marketed.

More than 730,000 children aged 9 and above in the Philippines have received at least one dose of the dengue vaccine, usually delivered in three doses.

There is no specific treatment for dengue and there are no other licensed vaccines on the market.  VOA